SCHEMBL5210482

SCHEMBL5210482

COc1cc(OC)cc(-c2ccc(N(C)CCN(C)c3ccc(-c4cc(OC)cc(OC)c4)nc3)cn2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
CYP1B1 Q16678 5/20 0.45
CYP1A1 P04798 4/20 0.45
CYP1A2 P05177 2/20 0.43
CYP2E1 P05181 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2C8 P10632 2/20 0.43
CYP2D6 P10635 2/20 0.43
CYP2A6 P11509 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP4B1 P13584 2/20 0.43
CYP2B6 P20813 2/20 0.43
CYP3A5 P20815 2/20 0.43
CYP2A7 P20853 2/20 0.43
CYP3A7 P24462 2/20 0.43
CYP2F1 P24903 2/20 0.43
CYP2C18 P33260 2/20 0.43
CYP2C19 P33261 2/20 0.43
CYP2J2 P51589 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5208648 0.94 NPC1 (0.46) NPC1RAB9ACYP1B1CYP1A1CYP1A2
SCHEMBL5207683 0.86 MTNR1A (0.40) NPC1RAB9ACYP1B1CYP1A1CYP1A2
SCHEMBL5206742 0.84 CRHR1 (0.41) CYP1A2CYP3A4CYP2D6CYP2C19CALM1
SCHEMBL5207852 0.82 FYN (0.43) RAB9A
SCHEMBL5210909 0.82 KDM1A (0.37) RAB9AKDM1AFGFR1FGFR2FGFR4
SCHEMBL5210498 0.82 NPC1 (0.46) NPC1RAB9ACYP1B1CYP1A1CYP1A2
SCHEMBL5203414 0.81 FGFR1 (0.38) KDM1AFGFR1FGFR2FGFR4FGFR3
SCHEMBL5208946 0.81 PDGFRB (0.37) KDM1A
SCHEMBL5207615 0.81 SMPD3 (0.41)
SCHEMBL5204509 0.81 KDM1A (0.46) KDM1AFGFR1FGFR2FGFR4FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1403251-B1 BIS(2-ARYL-5-PYRIDYL) DERIVATIVE KOWA CO (JP) 2007-07-18 EP disclosed
US-6890940-B2 Bis(2-aryl-5-pyridyl) derivatives KOWA CO., LTD. (JP) 2005-05-10 US disclosed
EP-1403251-A1 BIS(2-ARYL-5-PYRIDYL) DERIVATIVE Kowa Co., Ltd. (JP) 2004-03-31 EP disclosed
US-20030022886-A1 Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy KOWA CO., LTD. (JP) 2003-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022886-A1 Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy IGLV6-57, IL5, IGSF11 NPC1 4280/4885RAB9A 3915/4885CYP1B1 285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.